Perth, Australia (ABN Newswire) - MMJ PhytoTech Limited (ASX:MMJ) ("MMJ") notes significant progress made overnight with the Canadian Federal Government's Bill C-45 (The Cannabis Act) being approved by the Senate and moving through to the final approval stage of Royal Assent.

MMJ CEO comments

MMJ's CEO Jason Conroy commented that "We are very pleased that the federal legalisation of recreational cannabis in Canada is imminent and our portfolio is well positioned to participate in that large market opportunity."



About MMJ PhytoTech Ltd:

In October 2017, MMJ PhytoTech Limited (ASX:MMJ) announced its strategy to become an incubator for strategic investments across regulated jurisdictions globally covering the entire cannabis value chain.

Following the successful listing of United Greeneries Holdings Ltd ("United Greeneries") and Satipharm AG ("Satipharm") on the TSX-V through Harvest One Cannabis Inc. (CVE:HVT), MMJ has focused on the identification of a number of independent strategic investment opportunities that have the potential to deliver significant value to the Company's shareholders.

MMJ is actively pursuing early stage opportunities with the ability to deliver significant future revenue and the opportunity to provide dramatic global synergistic value as regulatory frameworks in key international markets continue to evolve. MMJ is targeting the full range of emerging cannabis-related sectors including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, R&D, hemp food products and retail.

MMJ currently holds an equity stake of 53,333,333 shares in Harvest One, 100% ownership of Israeli-based R&D division PhytoTech Therapeutics Limited ("PTL") and strategic holdings in e-Sense Lab Limited (ASX:ESE) and private Canadian-based company WeedMe Inc.



Source:

MMJ PhytoTech Ltd



Contact:

Investor and Media Enquiries:
Jason Conroy
Chief Executive Officer
T: +61-2-8098-0819
E: jconroy@mmjphytotech.com.au